

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 August 2024 (02.08.2024)



(10) International Publication Number
WO 2024/157205 A1

(51) International Patent Classification:

C07D 491/052 (2006.01) A61K 31/5025 (2006.01)
C07D 491/107 (2006.01) A61P 25/00 (2006.01)
C07D 491/18 (2006.01) A61P 29/00 (2006.01)
C07D 491/20 (2006.01)

(21) International Application Number:

PCT/IB2024/050721

(22) International Filing Date:

25 January 2024 (25.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/441,438 26 January 2023 (26.01.2023) US
63/589,626 11 October 2023 (11.10.2023) US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1 Doshomachi 4-chome, Chuoku, Osaka-shi, Osaka 541-0045 (JP).

(72) Inventors: **ADAMS, Mark E.**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Dr., San Diego, California 92121 (US). **BROWN, Jason W.**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Dr., San Diego, California 92121 (US). **CHANG, Ed-con**; c/o Takeda Development Center Americas, Inc., 9625 Towne Center Drive, San Diego, California 92121 (US). **SCHLEICHER, Kristin**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US). **TANG, Mingnam**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Dr., San Diego, California 92121 (US). **ZHOU, Feng**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US). **SUN, Huikai**; c/

o Takeda Development Center Americas, Inc., 9625 Towne Centre Dr., San Diego, California 92121 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: 1-AMINO-4-PHENYLPHthalazine DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES



(57) Abstract: Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein α , β , m , R⁵, R⁶, R⁷, R⁹, R¹⁰, R¹¹, R^a, R^b, X¹, X², X³, X⁴ and X⁸ are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with NLRP3.

WO 2024/157205 A1